Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LPCN 
Lipocine Inc (LPCN)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: LPCN (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.38
1 Year Target Price $7.38
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -3.33% | Avg. Invested days 19 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.85M USD | Price to earnings Ratio - | 1Y Target Price 7.38 |
Price to earnings Ratio - | 1Y Target Price 7.38 | ||
Volume (30-day avg) 2 | Beta 1.29 | 52 Weeks Range 2.65 - 6.17 | Updated Date 10/16/2025 |
52 Weeks Range 2.65 - 6.17 | Updated Date 10/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.84 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -107.11% | Operating Margin (TTM) -386.03% |
Management Effectiveness
Return on Assets (TTM) -16.76% | Return on Equity (TTM) -23.51% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -1190827 | Price to Sales(TTM) 4 |
Enterprise Value -1190827 | Price to Sales(TTM) 4 | ||
Enterprise Value to Revenue 0.62 | Enterprise Value to EBITDA 0.65 | Shares Outstanding 5419047 | Shares Floating 5261244 |
Shares Outstanding 5419047 | Shares Floating 5261244 | ||
Percent Insiders 2.91 | Percent Institutions 9.81 |
Upturn AI SWOT
Lipocine Inc
Company Overview
History and Background
Lipocine Inc. is a pharmaceutical company focused on developing innovative treatments for conditions related to metabolic and endocrine disorders. Founded in 2002, it has primarily focused on developing oral testosterone replacement therapies. Key milestones include various clinical trial phases for its lead product candidates.
Core Business Areas
- Endocrinology: Focuses on developing oral testosterone replacement therapies and related hormonal treatments.
Leadership and Structure
Dr. Mahesh Patel serves as Chairman, President, and CEO. The company has a typical corporate structure with departments for research and development, clinical trials, regulatory affairs, and finance.
Top Products and Market Share
Key Offerings
- Tlando: Tlando is an oral testosterone replacement therapy intended for adult males with conditions associated with a deficiency or absence of endogenous testosterone (hypogonadism). It has been approved by the FDA. Market share is difficult to specify due to recent market entrance and competition from established therapies such as Androgel (AbbVie; ABBV).
Market Dynamics
Industry Overview
The market for testosterone replacement therapies is large and growing, driven by an aging population and increased awareness of hypogonadism. Competition is intense, with various formulations available, including injectables, gels, and patches.
Positioning
Lipocine aims to differentiate itself with an oral formulation of testosterone, offering a potential convenience advantage over existing treatments.
Total Addressable Market (TAM)
The global testosterone replacement therapy market is projected to reach several billion USD annually. Lipocine aims to capture a portion of this market with Tlando by offering an oral dosage form that differentiates them from other methods.
Upturn SWOT Analysis
Strengths
- Oral formulation of testosterone
- FDA Approved
- Experienced Management Team
- Pipeline of potential products
Weaknesses
- Limited commercialization experience
- Reliance on single product
- Financial constraints
- Competition from established therapies
Opportunities
- Expansion into new markets
- Development of new formulations
- Partnerships with larger pharmaceutical companies
- Expansion of hypogonadism awareness through broader diagnostics
Threats
- Competition from generic testosterone products
- Regulatory hurdles
- Adverse events associated with testosterone therapy
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- ABBV
- ENDP
Competitive Landscape
Lipocine faces significant competition from larger pharmaceutical companies with established testosterone replacement therapies. Lipocine's advantage lies in its oral formulation but needs to overcome established brand loyalty and potential challenges in reimbursement.
Growth Trajectory and Initiatives
Historical Growth: Lipocine's historical growth has been primarily driven by clinical trial progress and regulatory milestones. Revenue generation is relatively recent with Tlando.
Future Projections: Future growth depends on market acceptance of Tlando and successful development of other pipeline products. Analyst estimates vary based on assumptions about market share and commercialization.
Recent Initiatives: Recent initiatives include commercial launch of Tlando, pursuing additional regulatory approvals and strategic partnerships.
Summary
Lipocine is a pharmaceutical company with an FDA-approved oral testosterone replacement therapy, Tlando. While Tlando has market potential, Lipocine faces competition from established treatments and generic alternatives, demanding efficient commercialization. The company's financial health depends on successful revenue generation and strategic partnerships. Investors should watch for Tlando's market acceptance and the progress of its pipeline programs as indicators of future growth. The company needs to make sure they handle their business carefully while competing with much larger companies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings
- Lipocine Investor Relations
- Industry Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share figures are estimates and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Lipocine Inc
Exchange NASDAQ | Headquaters Salt Lake City, UT, United States | ||
IPO Launch date 2013-10-22 | Co-Founder, Interim Principal Financial Officer, Director, President & CEO Dr. Mahesh V. Patel Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 16 | Website https://www.lipocine.com |
Full time employees 16 | Website https://www.lipocine.com | ||
Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the treatment of cirrhosis; LPCN 1154 to treat postpartum depression; LPCN 2101, a NAS candidate for women with epilepsy; and LPCN 2203, an oral candidate for management of essential tremor. It also develops LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of metabolic dysfunction-associated steatohepatitis; LPCN 2401 to improve body composition in obesity management; and LPCN 1107, an oral hydroxy progesterone caproate product indicated for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.